000028 国药一致
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入37,785,981-1.57%75,477,48573,443,13768,357,81059,649,455
减:营业总成本37,024,016-0.60%73,277,09771,309,68866,519,74757,817,567
    其中:营业成本33,643,136-0.87%66,425,42664,516,92660,339,29852,591,767
               财务费用120,39563.23%204,535189,514212,483119,855
               资产减值损失(9,739)284.69%(17,577)(71,588)(242,905)(5,179)
公允价值变动收益3,149-81.93%(15,161)28,871----
投资收益190,05722.09%237,029139,131292,381283,952
    其中:对联营企业和合营企业的投资收益227,26544.83%315,446298,527333,397354,346
营业利润948,860-26.74%2,467,4252,306,0691,952,4112,163,841
利润总额957,969-25.83%2,473,2272,311,0701,974,8532,157,236
减:所得税费用187,914-28.35%514,739539,332447,211435,940
净利润770,055-25.19%1,958,4871,771,7381,527,6421,721,296
减:非控股权益26,567-86.66%359,231285,030191,214319,404
股东净利润743,487-10.45%1,599,2561,486,7081,336,4281,401,893

市场价值指针
每股收益 (元) *1.340-10.07%2.8702.6703.1203.270
每股派息 (元) *----0.6800.8000.6000.800
每股净资产 (元) *31.9467.02%31.29037.66634.86132.580
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容